Optimal Protocols for the Anti-VEGF Tumor Treatment

被引:2
|
作者
Poleszczuk, J. [1 ]
Piotrowska, M. J. [2 ]
Forys, U. [2 ]
机构
[1] Univ Warsaw, Coll Inter Fac Individual Studies Math & Nat Sci, PL-02089 Warsaw, Poland
[2] Univ Warsaw, Fac Math Informat & Mech, PL-02097 Warsaw, Poland
关键词
angiogenesis; bevacizumab; optimal control; cancer; ANTIANGIOGENIC THERAPY; ANGIOGENESIS; CANCER; MODEL;
D O I
10.1051/mmnp/20149412
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Cancer treatment using the antiangiogenic agents targets the evolution of the tumor vasculature. The aim is to significantly reduce supplies of oxygen and nutrients, and thus starve the tumor and induce its regression. In the paper we consider well established family of tumor angiogenesis models together with their recently proposed modification, that increases accuracy in the case of treatment using VEGF antibodies. We consider the optimal control problem of minimizing the tumor volume when the maximal admissible drug dose (the total amount of used drug) and the final level of vascularization are also taken into account. We investigate the solution of that problem for a fixed therapy duration. We show that the optimal strategy consists of the drug-free, full-dose and singular (with intermediate values of the control variable) intervals. Moreover, no bang-bang switch of the control is possible, that is the change from the no-dose to full-dose protocol (or in opposite direction) occurs on the interval with the singular control. For two particular models, proposed by Hahnfeldt et al. and Ergun et al., we provide additional theorems about the optimal control structure. We investigate the optimal controls numerically using the customized software written in MATLAB (R), which we make freely available for download. Utilized numerical scheme is based on the composition of the well known gradient and shooting methods.
引用
收藏
页码:204 / 215
页数:12
相关论文
共 50 条
  • [21] Anti-VEGF treatment for retinal angiomatous proliferation
    Wolf, A.
    Kook, D.
    Kreutzer, T.
    Gandorfer, A.
    Haritoglou, C.
    Kampik, A.
    Ulbig, M.
    OPHTHALMOLOGE, 2008, 105 (09): : 845 - 851
  • [22] Anti-VEGF, a new era for DMLA treatment
    Girmens, Jean-Francois
    BIOFUTUR, 2012, (332) : 48 - 49
  • [23] Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
    Keunen, Olivier
    Johansson, Mikael
    Oudin, Anais
    Sanzey, Morgane
    Rahim, Siti A. Abdul
    Fack, Fred
    Thorsen, Frits
    Taxt, Torfinn
    Bartos, Michal
    Jirik, Radovan
    Miletic, Hrvoje
    Wang, Jian
    Stieber, Daniel
    Stuhr, Linda
    Moen, Ingrid
    Rygh, Cecilie Brekke
    Bjerkvig, Rolf
    Niclou, Simone P.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (09) : 3749 - 3754
  • [24] Anti-VEGF in the retina
    Ng, E.
    ACTA OPHTHALMOLOGICA, 2014, 92
  • [25] Anti-VEGF and Beyond
    Bertelmann, T.
    Kaymak, H.
    Kretz, F. T. A.
    Koss, M. J.
    JOURNAL OF OPHTHALMOLOGY, 2017, 2017
  • [26] Pharmakologische Basis der Anti-VEGF TherapiePharmacological basis of the anti-VEGF therapy
    Leopold Schmetterer
    Gerhard Garhöfer
    Spektrum der Augenheilkunde, 2012, 26 (4) : 185 - 196
  • [27] Review of effects of anti-VEGF treatment on refractive error
    Mintz-Hittner, Helen A.
    Geloneck, Megan M.
    EYE AND BRAIN, 2016, 8 : 135 - 140
  • [29] Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
    Ria, Roberto
    Melaccio, Assunta
    Racanelli, Vito
    Vacca, Angelo
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06) : 1 - 27
  • [30] Photoreceptor Integrity Predicts Response to Anti-VEGF Treatment
    Achiron, Asaf
    Kydyrbaeva, Ayana
    Man, Vitaly
    Lagstein, Oded
    Burgansky, Zvia
    Blumenfeld, Oren
    Bar, Asaf
    Bartov, Elisha
    OPHTHALMIC RESEARCH, 2017, 57 (01) : 37 - 41